Company Reports / F. Hoffmann-La Roche LTD.
COMPANY: F. Hoffmann-La Roche LTD.
INDEX RANK: 5th
Total Impact Score: 8,470,126.91
F. Hoffmann-La Roche LTD. is ranked 5th place in our index for 2015. F. Hoffmann-La Roche LTD.’s drugs have a total impact score of 8,470,126.91. F. Hoffmann-La Roche Ltd treats one disease in our model - DS-TB - with one total drug - Isoniazid (H or INH). F. Hoffmann-La Roche Ltd receives credit for one treatment against DS-TB - Isoniazid (H or INH). This one drug averted 8,470,126.91 of the total DALYS for DS-TB, which is 25.00% of the worldwide DALYs that we estimate would have been lost due to DS-TB in 2015 in the absence of effective treatment. F. Hoffmann-La Roche Ltd’s drug portfolio placed it in a tie for 1st in terms of total averted DALYs for DS-TB.
Company Score Breakdown:
Isoniazid (H) is the most common front line treatment for drug-susceptible tuberculosis, first introduced in 1954, and is also used as an add-on agent to treat multidrugresistant TB. Side effects include hepatitis and gastrointestinal upset. The earliest patent for Isoniazid was by Hoffman La Roche in 1952.
SULFADOXINE - PYRIMETHAMINE (SP)
Sulfadoxine - Pyrimethamine (SP) is a combination of a diamino-pyrimidine, similar in structure and activity to proguanil, and a sulfonamide, known to have synergistic antimalarial effects with pyrimethamine. While still used to treat patients with sensitivity to other antimalarial agents, due to high rates of resistance and a high potential hepatotoxicity, it is recommended by the WHO only as a part of artemisinin-based combination therapy or in intermittent preventive therapy of special risk groups such as pregnant women and infants.
Headquartered in Switzerland, Hoffman-LaRoche is a global pharmaceutical company founded by Fritz Hoffmann-La Roche in 1896. They focus primarily on in-vitro diagnostics, cancer medication, and drugs for viral infections, inflammatory diseases and CNS disorders. Some of their key products include Herceptin®, MabThera®/Rituxan® and Perjeta®. In 1934, they became the first company to mass-produce synthetic vitamin C, which was branded as Redoxon. Roche, in collaboration with the Clinton Health Care Initiative and other organisations, supervise the Global Access Programme for HIV as they work to diagnose and treat individuals in low and middle income countries. In collaboration with the Medicine Patent Pool, they have made Valcyte available for HIV/AIDS programs at close to non-profit prices in 138 countries. They have several projects running that aim to improve cancer care in developing countries. Currently, the Swiss firm Novartis owns a third of its shares. In 2017, Hoffman LaRoche reported revenue of about $53 billion with 93,734 employees in more than 100 countries.